Abstract
We congratulate Bonner and colleagues for their updated 5-year survival analysis of radiotherapy plus cetuximab for locoregionally advanced head and neck cancer. 1 Bonner JA Harari PM Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010; 11: 21-28 Summary Full Text Full Text PDF PubMed Scopus (1517) Google Scholar Regrettably, the authors have chosen not to update the primary endpoint, locoregional control, which makes it more difficult for the readers to interpret the study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
